SalioGen Therapeutics Strengthens its Leadership Team to Advance its Gene Coding™ Platform CAMBRIDGE, Mass. – July 20, 2022 – SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine, today announced the expansion of its leadership team with the addition of five highly accomplished scientists, physicians and biotech industry …
SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene CodingTM – A New Category of Genetic Medicine CAMBRIDGE, Mass. – January 05, 2022 – SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine, today announced the completion of an oversubscribed and up-sized $115 million Series …
SalioGen Therapeutics Appoints Esteemed Industry Veterans to Executive Advisory Board John Maraganore, Ph.D., Mark McClellan, M.D., Ph.D. and Andrew Lo, Ph.D. appointed as Executive Advisors to support SalioGen’s efforts to realize the full potential of its novel Gene CodingTM platform CAMBRIDGE, Mass. – November 10, 2021 – SalioGen Therapeutics, a privately held biotechnology company developing …
SalioGen Therapeutics Appoints Esteemed Industry Veterans to Executive Advisory Board Read More »
SalioGen Therapeutics Strengthens Management with Key Additions to Leadership Team to Advance Its Gene Coding Platform Sung You, M.S., MBA, appointed as Chief Business and Strategy Officer Nancy L. Craig, Ph.D., appointed as Senior Vice President of Genetic Engineering and Mobile Elements Sandeep Nema, Ph.D., appointed as Senior Vice President of Technical Operations CAMBRIDGE, Mass. …
A new biotech is emerging from stealth to develop what its CEO calls “third-generation gene therapy.”
Founded by former Human Genome Project researcher Joseph Higgins, SalioGen Therapeutics launched Monday with $20 million in Series A funding.
SalioGen Therapeutics has raised $20 million to validate a platform designed to eliminate barriers to the use of gene therapies. The series A will support preclinical validation of mammal-derived enzyme saliogase in the creation of in vivo gene therapies for familial hypercholesterolemia and inherited macular degeneration.
